The Effect of Early Oxybutynin Treatment on Posterior Urethral Valve Outcomes: A Randomized Controlled Trial.
To study the effect of oxybutynin treatment on the bladder and upper urinary tract outcomes following posterior urethral valve (PUV) ablation in infancy. Infants less than 12 months diagnosed with PUV and treated with primary endoscopic valve ablation (EVA), were screened for eligibility. Patients treated with urinary diversion and those with other conditions that could affect the lower urinary tract function were excluded. Patients were randomized to either oxybutynin treatment (0.2 mg/kg TDS) till toilet training or active observation. The study endpoints were serum creatinine (Sr.Cr), eGFR, hydronephrosis and vesicoureteral reflux (VUR) resolution, febrile UTI and toilet training. Between December 2013 and September 2015, a total of 49 infants (24 in oxybutynin and 25 in the observation group) were enrolled and completed at least one year of follow-up. Oxybutynin was discontinued before toilet training in 5 patients (flushing in two, bladder and upper tract dilation in two and cognitive changes in one patient). After a median follow-up of 44.2 (12-57.6) months, median Sr.Cr and eGFR were not significantly different between both groups (p=0.823 and 0.722, respectively). Renal units in the oxybutynin group had a higher likelihood of hydronephrosis improvement (61.9% vs. 34.8%, p=0.011) and VUR resolution (62.5% vs. 25%, p=0.023). Febrile UTI (29.2% vs. 40%, p=0.404), achievement (70.8% vs. 76%, p=0.748) or age at toilet training (p=0.247) were not different between oxybutynin and observation groups, respectively. Oxybutynin enhances hydronephrosis and VUR resolution following primary EVA in infancy, but periodic monitoring is warranted.